Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Bartter syndrome in which the cause of the disease is a mutation in the KCNJ1 gene.
Features include always present findings: Hypercalciuria, Increased circulating renin concentration, Hypokalemia, and Increased circulating aldosterone concentration and others; and very common findings: Nephrocalcinosis. 47 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 5 | Nephrocalcinosis, Increased urinary potassium, Renal potassium wasting |
Brain and nerves | 4 | Seizure, Intellectual disability, Paresthesia |
Muscles | 4 | Muscle spasm, Generalized muscle weakness, Renal potassium wasting |
Digestive system | 3 | Constipation, Diarrhea, Vomiting |
Growth and development | 2 | Short stature, Failure to thrive |
Lab test results | 2 | Increased circulating renin concentration, Increased circulating aldosterone concentration |
Head and neck | 2 | Triangular face, Macrocephaly |
Metabolism | 2 | Fever, Hypokalemic metabolic alkalosis |
Bones and joints | 1 | Mild bone density loss (osteopenia) |
Pregnancy and birth | 1 | Fetal polyuria |
Blood and immune system | 1 | Impaired platelet aggregation |
KCNJ1 encodes potassium inwardly rectifying channel subfamily J member 1 (391 aa). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Highest expression in Kidney Medulla (91.2 TPM) and Kidney Cortex (40.6 TPM).
Bartter disease type 2 is caused by mutations in the KCNJ1 gene on chromosome 11.
The KCNJ1 protein participates in KCNJ11 tetramer:ABCC8 mutants and KCNJ11:ATP tetramer:ABCC8 tetramer pathways.
KCNJ1 is classified as a druggable target (Druggable Genome and Ion Channel categories) with score 4.4.
Genetic testing for KCNJ1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Bartter disease type 2 has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 1 very common feature.
No clinical trials have been registered for Bartter disease type 2.
18 publications have been identified in PubMed for Bartter disease type 2. Research spans Case Report / Case Series (61%), Review / Meta-Analysis (22%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 61% |
Research summaries | 4 | 22% |
Testing and diagnosis research | 2 | 11% |
Laboratory research | 1 | 6% |
Engel O (2026). [PMID: 42079331](https://pubmed.ncbi.nlm.nih.gov/42079331/). *Clin Med Insights Pediatr*. [Case Report / Case Series]
Rivetti G (2026). [PMID: 41517599](https://pubmed.ncbi.nlm.nih.gov/41517599/). *Journal of clinical medicine*. [Review / Meta-Analysis]
Czubilińska-Łada J (2026). [PMID: 41883686](https://pubmed.ncbi.nlm.nih.gov/41883686/). *Frontiers in pediatrics*. [Case Report / Case Series]
Dahiya A (2026). [PMID: 41711945](https://pubmed.ncbi.nlm.nih.gov/41711945/). *Pediatric nephrology (Berlin, Germany)*. [Case Report / Case Series]
Fang C (2025). [PMID: 39283520](https://pubmed.ncbi.nlm.nih.gov/39283520/). *Pediatric nephrology (Berlin, Germany)*. [Review / Meta-Analysis]
Roodaki N (2025). [PMID: 40083561](https://pubmed.ncbi.nlm.nih.gov/40083561/). *Case reports in genetics*. [Case Report / Case Series]
Baligeri K (2025). [PMID: 41378233](https://pubmed.ncbi.nlm.nih.gov/41378233/). *Clinical nephrology. Case studies*. [Case Report / Case Series]
Xiao L (2025). [PMID: 41069163](https://pubmed.ncbi.nlm.nih.gov/41069163/). *Nephrology (Carlton, Vic.)*. [Case Report / Case Series]
Glassner VO (2025). [PMID: 41330877](https://pubmed.ncbi.nlm.nih.gov/41330877/). *Prenatal diagnosis*. [Diagnostic / Biomarker]
Vadher A (2025). [PMID: 41472911](https://pubmed.ncbi.nlm.nih.gov/41472911/). *Case reports in nephrology*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:58 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Bartter disease type 2
AI-curated news mentioning Bartter disease type 2
Updated Jul 21, 2026
FDA approved Casgevy CRISPR gene therapy for children as young as 2 with sickle cell disease on July 1, 2026. Here's what families need to know about this milestone. Approximately 5,500 additional American children are now eligible for this established one-time therapy, according to Vertex Pharmaceuticals, Casgevy's developer. Casgevy also covers transfusion-dependent beta-thalassemia in this new age indication. Sickle cell disease is a lifelong inherited blood disorder that warps red blood cells into stiff, crescent shapes that can block blood flow, starving organs and tissues of oxygen. The world's first CRISPR-based gene therapy has been approved for children as young as two years old, opening the possibility of a single, potentially curative treatment to thousands of American children with sickle cell disease before years of organ damage can narrow what medicine can do for them. Families with children aged 2 and older who have sickle cell disease should speak with their pediatric hematologist about whether Casgevy is appropriate to consider at this stage of their child's disease. Ask specifically which authorized treatment centers perform Casgevy in your region. Treatment is available only at specialized sites, and geographic access remains limited. Contact your child's insurance plan or Medicaid office to ask about coverage. Medicaid coverage for gene therapies varies by state, and some states have developed outcomes-based payment models for high-cost therapies. "With today's decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases," said Karim Mikhail, acting director of the Office of Therapeutic Products at the FDA's Center for Biologics Evaluation and Research, according to the FDA press announcement. Casgevy is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy.